Showing results (361-370 of 396) with videos related to
Sort By:
Pageof 40
Nature|September 28, 2017
PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomasHezhe Lu, Shujing Liu, Gao Zhang, et al.Nature|September 9, 2010
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaGideon Bollag, Peter Hirth, James Tsai, et al.Nature|November 26, 2010
COT drives resistance to RAF inhibition through MAP kinase pathway reactivationCory M Johannessen, Jesse S Boehm, So Young Kim, et al.Nature|December 12, 2018
Author Correction: PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomasHezhe Lu, Shujing Liu, Gao Zhang, et al.Biorxiv : the Preprint Server for Biology|December 3, 2025
Lymphotoxin-driven cancer cell eradication by tumoricidal CD8+ TILHongyan Xie, Aiping Jiang, Aonkon Dey, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2018
Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant MelanomaGao Zhang, Lawrence W Wu, Ilgen Mender, et al.Nature Medicine|May 4, 2021
Evolution of delayed resistance to immunotherapy in a melanoma responderDavid Liu, Jia-Ren Lin, Emily J Robitschek, et al.Nature Medicine|June 5, 2025
Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanomaKelsey R Monson, Robert Ferguson, Joanna E Handzlik, et al.Cell|November 3, 2018
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in MelanomaMoshe Sade-Feldman, Keren Yizhak, Stacey L Bjorgaard, et al.Cell Reports|June 3, 2026
Melanoma-patient-derived xenograft multi-omics resource melPDomiX maps gain- and loss-of-function alterationsKonstantinos Tsingas, Monzy Thomas, McKenna Reale, et al.Pageof 40